We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Granted FDA Emergency Use Authorization for Cobas SARS-CoV-2 & Influenza A/B Test

By LabMedica International staff writers
Posted on 17 Sep 2020
Roche (Basel, Switzerland) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a rapid version of its Cobas SARS-CoV-2 & Influenza A/B test. More...


The cobas SARS-CoV-2 & Influenza A/B Test is a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A virus, and Influenza B virus in nasal or nasopharyngeal swab samples collected from individuals suspected of a respiratory infection, and is not intended for the detection of Influenza C virus.

The test is designed to run on Roche’s benchtop Cobas Liat system, which is a fast, easy-to-use, compact PCR system designed for on-demand testing in point-of-care settings such as physician clinics, pharmacies, and hospital and satellite laboratories. The fully-automated analyzer with touchscreen guided operation is smaller than a shoebox and conveniently designed for space-challenged testing locations. Single assay runs allow time-sensitive testing and reporting, while its sealed-tube design eliminates operator contact with reagents or other chemicals.

The latest EUA for the Roche test gives the new option of conducting rapid testing in either point-of-care or clinical laboratory settings to detect and differentiate between the viruses. The rapid diagnostic, which gives results for single samples within 20 minutes, is the second EUA for the Roche combination test. Earlier this month, Roche had received EUA from the FDA for a version of the Cobas SARS-CoV-2 & Influenza A/B test designed to run on its Cobas 6800/8800 systems, which provide results in about three hours. This was also the FDA's fifth EUA for such a combination diagnostic amidst the approaching flu season.



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.